1. Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine. Issue 7 (14th June 2019) Authors: Oo, Zay Yar; Proctor, Martina; Stevenson, Alexander J.; Nazareth, Deborah; Fernando, Madushan; Daignault, Sheena M.; Lanagan, Catherine; Walpole, Sebastian; Bonazzi, Vanessa; Škalamera, Dubravka; Snell, Cameron; Haass, Nikolas K.; Larsen, Jill E.; Gabrielli, Brian Journal: Molecular oncology Issue: Volume 13:Issue 7(2019) Page Start: 1503 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Microsimulation Model for Evaluating the Cost-Effectiveness of Surveillance in BAP1 Pathogenic Variant Carriers. (2021) Authors: Walpole, Sebastian; Hayward, Nicholas K.; Pritchard, Antonia L.; Johansson, Peter A. Journal: JCO Clinical Cancer Informatics Issue: Volume 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗